Brief: Hutchmed (China) Updates FY25 Guidance For Oncology/Immunology Consol Rev To $270M - $350M

HUTCHMED (China)

07/08/2025 16:13

Aug 7 (Reuters) - HUTCHMED (China) Ltd 0013.HK:

UPDATES FY25 GUIDANCE FOR ONCOLOGY/IMMUNOLOGY CONSOL REVENUE TO $270 MILLION - $350 MILLION

Further company coverage: 0013.HK

 ((Reuters.Briefs@thomsonreuters.com;))